Other content in this Stream
Prometic reports financial results for second quarter 2019
Prometic today announced financial results for its fiscal 2019 second quarter ended June 30th 2019.
Correction of previous press release: Prometic to report its second quarter financial results and hold conference call
Prometic’s conference call will be held at 8:30 a.m. (EDT), rather than 11:00 a.m. (EDT) on Tuesday, August 13th, 2019.
Prometic to report its second quarter financial results and hold conference call
Prometic will report its financial results for the second quarter ended June 30th, 2019 on Monday August 12th, 2019 after market close.
Annual Report 2018
2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.
Quarterly Report 2018 Q3
Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.
Quarterly Report Q2 2018
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
Board of Directors Charter 2019
Audit, Risk and Finance Committee Charter 2017
The Committee is mainly responsible for the corporation's financial reporting process, process to identify & manage risks, internal & external audit process, communication systems & capital structure.
Chairman Mandate 2018
The chairman of the Board of Directors of Prometic Life Sciences Inc. chairs the meetings of the Board and assures its good functioning and the good functioning of the committees of the Board.
Virtual Tour of Prometic Life Science's Manufacturing Process
You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment